#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-4	Gray	_
1-2	5-11	matter	_
1-3	12-25	morphological	_
1-4	26-35	anomalies	_
1-5	36-38	in	_
1-6	39-42	the	_
1-7	43-53	cerebellar	_
1-8	54-60	vermis	_
1-9	61-63	in	_
1-10	64-77	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-11	78-91	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-12	92-100	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-13	101-105	with	_
1-14	106-115	cognitive	_
1-15	116-124	deficits	_
1-16	125-135	Background	_
1-17	136-145	Cognitive	_
1-18	146-154	deficits	_
1-19	155-158	are	_
1-20	159-160	a	_
1-21	161-165	core	_
1-22	166-173	feature	_
1-23	174-176	of	_
1-24	177-182	early	_
1-25	183-196	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-26	197-198	.	_

2-1	199-206	However	_
2-2	207-208	,	_
2-3	209-212	the	_
2-4	213-225	pathological	_
2-5	226-237	foundations	_
2-6	238-248	underlying	_
2-7	249-258	cognitive	_
2-8	259-267	deficits	_
2-9	268-271	are	_
2-10	272-277	still	_
2-11	278-285	unknown	_
2-12	286-287	.	_

3-1	288-291	The	_
3-2	292-299	present	_
3-3	300-305	study	_
3-4	306-314	examined	_
3-5	315-318	the	_
3-6	319-330	association	_
3-7	331-338	between	_
3-8	339-343	gray	_
3-9	344-350	matter	_
3-10	351-358	density	_
3-11	359-362	and	_
3-12	363-372	cognitive	_
3-13	373-381	deficits	_
3-14	382-384	in	_
3-15	385-398	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-16	399-412	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-17	413-414	.	_

4-1	415-421	Method	_
4-2	422-432	Structural	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
4-3	433-441	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
4-4	442-451	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
4-5	452-459	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
4-6	460-462	of	_
4-7	463-466	the	_
4-8	467-472	brain	_
4-9	473-476	was	_
4-10	477-486	performed	_
4-11	487-489	in	_
4-12	490-492	34	_
4-13	493-506	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
4-14	507-520	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
4-15	521-529	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
4-16	530-533	and	_
4-17	534-536	21	_
4-18	537-544	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-19	545-553	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-20	554-555	.	_

5-1	556-564	Patients	_
5-2	565-569	were	_
5-3	570-577	divided	_
5-4	578-582	into	_
5-5	583-586	two	_
5-6	587-596	subgroups	_
5-7	597-606	according	_
5-8	607-609	to	_
5-9	610-617	working	_
5-10	618-624	memory	_
5-11	625-629	task	_
5-12	630-641	performance	_
5-13	642-643	.	_

6-1	644-647	The	_
6-2	648-653	three	_
6-3	654-660	groups	_
6-4	661-665	were	_
6-5	666-670	well	_
6-6	671-678	matched	_
6-7	679-682	for	_
6-8	683-686	age	_
6-9	687-688	,	_
6-10	689-695	gender	_
6-11	696-697	,	_
6-12	698-701	and	_
6-13	702-711	education	_
6-14	712-713	,	_
6-15	714-717	and	_
6-16	718-721	the	_
6-17	722-725	two	_
6-18	726-733	patient	_
6-19	734-740	groups	_
6-20	741-745	were	_
6-21	746-750	also	_
6-22	751-758	further	_
6-23	759-766	matched	_
6-24	767-770	for	_
6-25	771-780	diagnosis	_
6-26	781-782	,	_
6-27	783-791	duration	_
6-28	792-794	of	_
6-29	795-802	illness	_
6-30	803-804	,	_
6-31	805-808	and	_
6-32	809-822	antipsychotic	_
6-33	823-832	treatment	_
6-34	833-834	.	_

7-1	835-846	Voxel-based	_
7-2	847-859	morphometric	_
7-3	860-868	analysis	_
7-4	869-872	was	_
7-5	873-882	performed	_
7-6	883-885	to	_
7-7	886-894	estimate	_
7-8	895-902	changes	_
7-9	903-905	in	_
7-10	906-910	gray	_
7-11	911-917	matter	_
7-12	918-925	density	_
7-13	926-928	in	_
7-14	929-942	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
7-15	943-956	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
7-16	957-965	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
7-17	966-970	with	_
7-18	971-980	cognitive	_
7-19	981-989	deficits	_
7-20	990-991	.	_

8-1	992-995	The	_
8-2	996-1009	relationships	_
8-3	1010-1017	between	_
8-4	1018-1022	gray	_
8-5	1023-1029	matter	_
8-6	1030-1037	density	_
8-7	1038-1041	and	_
8-8	1042-1050	clinical	_
8-9	1051-1059	outcomes	_
8-10	1060-1064	were	_
8-11	1065-1073	explored	_
8-12	1074-1075	.	_

9-1	1076-1083	Results	_
9-2	1084-1092	Patients	_
9-3	1093-1097	with	_
9-4	1098-1107	cognitive	_
9-5	1108-1116	deficits	_
9-6	1117-1121	were	_
9-7	1122-1127	found	_
9-8	1128-1130	to	_
9-9	1131-1135	have	_
9-10	1136-1143	reduced	_
9-11	1144-1148	gray	_
9-12	1149-1155	matter	_
9-13	1156-1163	density	_
9-14	1164-1166	in	_
9-15	1167-1170	the	_
9-16	1171-1177	vermis	_
9-17	1178-1181	and	_
9-18	1182-1188	tonsil	_
9-19	1189-1191	of	_
9-20	1192-1202	cerebellum	_
9-21	1203-1211	compared	_
9-22	1212-1216	with	_
9-23	1217-1225	patients	_
9-24	1226-1233	without	_
9-25	1234-1243	cognitive	_
9-26	1244-1252	deficits	_
9-27	1253-1256	and	_
9-28	1257-1264	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-29	1265-1273	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-30	1274-1275	,	_
9-31	1276-1285	decreased	_
9-32	1286-1290	gray	_
9-33	1291-1297	matter	_
9-34	1298-1305	density	_
9-35	1306-1308	in	_
9-36	1309-1313	left	_
9-37	1314-1327	supplementary	_
9-38	1328-1333	motor	_
9-39	1334-1338	area	_
9-40	1339-1340	,	_
9-41	1341-1350	bilateral	_
9-42	1351-1361	precentral	_
9-43	1362-1367	gyrus	_
9-44	1368-1376	compared	_
9-45	1377-1381	with	_
9-46	1382-1390	patients	_
9-47	1391-1398	without	_
9-48	1399-1408	cognitive	_
9-49	1409-1417	deficits	_
9-50	1418-1419	.	_

10-1	1420-1430	Classifier	_
10-2	1431-1438	results	_
10-3	1439-1445	showed	_
10-4	1446-1449	GMD	_
10-5	1450-1452	in	_
10-6	1453-1463	cerebellar	_
10-7	1464-1470	vermis	_
10-8	1471-1477	tonsil	_
10-9	1478-1485	cluster	_
10-10	1486-1491	could	_
10-11	1492-1505	differentiate	_
10-12	1506-1511	SZ-CD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-13	1512-1516	from	_
10-14	1517-1525	controls	_
10-15	1526-1527	,	_
10-16	1528-1532	left	_
10-17	1533-1546	supplementary	_
10-18	1547-1552	motor	_
10-19	1553-1557	area	_
10-20	1558-1565	cluster	_
10-21	1566-1571	could	_
10-22	1572-1585	differentiate	_
10-23	1586-1591	SZ-CD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-24	1592-1596	from	_
10-25	1597-1603	SZ-NCD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-26	1604-1605	.	_

11-1	1606-1610	Gray	_
11-2	1611-1617	matter	_
11-3	1618-1625	density	_
11-4	1626-1632	values	_
11-5	1633-1635	of	_
11-6	1636-1639	the	_
11-7	1640-1650	cerebellar	_
11-8	1651-1657	vermis	_
11-9	1658-1665	cluster	_
11-10	1666-1668	in	_
11-11	1669-1677	patients	_
11-12	1678-1684	groups	_
11-13	1685-1689	were	_
11-14	1690-1700	positively	_
11-15	1701-1711	correlated	_
11-16	1712-1716	with	_
11-17	1717-1726	cognitive	_
11-18	1727-1735	severity	_
11-19	1736-1737	.	_

12-1	1738-1749	Conclusions	_
12-2	1750-1759	Decreased	_
12-3	1760-1764	gray	_
12-4	1765-1771	matter	_
12-5	1772-1779	density	_
12-6	1780-1782	in	_
12-7	1783-1786	the	_
12-8	1787-1793	vermis	_
12-9	1794-1797	and	_
12-10	1798-1804	tonsil	_
12-11	1805-1807	of	_
12-12	1808-1818	cerebellum	_
12-13	1819-1822	may	_
12-14	1823-1831	underlie	_
12-15	1832-1837	early	_
12-16	1838-1847	psychosis	_
12-17	1848-1851	and	_
12-18	1852-1857	serve	_
12-19	1858-1860	as	_
12-20	1861-1862	a	_
12-21	1863-1872	candidate	_
12-22	1873-1882	biomarker	_
12-23	1883-1886	for	_
12-24	1887-1900	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-25	1901-1905	with	_
12-26	1906-1915	cognitive	_
12-27	1916-1924	deficits	_
12-28	1925-1926	.	_

13-1	1927-1934	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
13-2	1935-1943	Subjects	_
13-3	1944-1946	We	_
13-4	1947-1956	recruited	_
13-5	1957-1968	fifty-eight	_
13-6	1969-1981	right-handed	_
13-7	1982-1994	participants	_
13-8	1995-1996	.	_

14-1	1997-2002	Among	_
14-2	2003-2007	them	_
14-3	2008-2009	,	_
14-4	2010-2022	thirty-seven	_
14-5	2023-2036	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
14-6	2037-2045	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
14-7	2046-2056	determined	_
14-8	2057-2059	by	_
14-9	2060-2063	the	_
14-10	2064-2074	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-11	2075-2083	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-12	2084-2093	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-13	2094-2097	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-14	2098-2108	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-15	2109-2112	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-16	2113-2124	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-17	2125-2131	Manual	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-18	2132-2135	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-19	2136-2142	Mental	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-20	2143-2152	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
14-21	2153-2159	Fourth	_
14-22	2160-2167	Edition	_
14-23	2168-2169	(	_
14-24	2170-2176	DSM-IV	_
14-25	2177-2178	)	_
14-26	2179-2183	Axis	_
14-27	2184-2185	I	_
14-28	2186-2195	Disorders	_
14-29	2196-2197	,	_
14-30	2198-2205	Patient	_
14-31	2206-2213	Edition	_
14-32	2214-2215	(	_
14-33	2216-2224	SCID-I/P	_
14-34	2225-2226	)	_
14-35	2227-2228	,	_
14-36	2229-2233	were	_
14-37	2234-2243	recruited	_
14-38	2244-2248	from	_
14-39	2249-2252	the	_
14-40	2253-2263	Department	_
14-41	2264-2266	of	_
14-42	2267-2277	Psychiatry	_
14-43	2278-2279	,	_
14-44	2280-2286	Second	_
14-45	2287-2294	Xiangya	_
14-46	2295-2303	Hospital	_
14-47	2304-2306	of	_
14-48	2307-2314	Central	_
14-49	2315-2320	South	_
14-50	2321-2331	University	_
14-51	2332-2333	,	_
14-52	2334-2342	Changsha	_
14-53	2343-2344	,	_
14-54	2345-2350	China	_
14-55	2351-2352	.	_

15-1	2353-2355	We	_
15-2	2356-2364	required	_
15-3	2365-2368	all	_
15-4	2369-2377	patients	_
15-5	2378-2380	to	_
15-6	2381-2385	have	_
15-7	2386-2388	at	_
15-8	2389-2394	least	_
15-9	2395-2396	9	_
15-10	2397-2402	years	_
15-11	2403-2405	of	_
15-12	2406-2415	education	_
15-13	2416-2417	,	_
15-14	2418-2420	to	_
15-15	2421-2425	have	_
15-16	2426-2430	been	_
15-17	2431-2440	diagnosed	_
15-18	2441-2445	with	_
15-19	2446-2459	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-20	2460-2466	within	_
15-21	2467-2470	the	_
15-22	2471-2475	past	_
15-23	2476-2478	18	_
15-24	2479-2485	months	_
15-25	2486-2487	,	_
15-26	2488-2491	and	_
15-27	2492-2494	to	_
15-28	2495-2499	have	_
15-29	2500-2502	no	_
15-30	2503-2510	history	_
15-31	2511-2513	of	_
15-32	2514-2521	chronic	_
15-33	2522-2534	neurological	_
15-34	2535-2542	disease	_
15-35	2543-2544	,	_
15-36	2545-2554	substance	_
15-37	2555-2560	abuse	_
15-38	2561-2562	,	_
15-39	2563-2580	electroconvulsive	_
15-40	2581-2588	therapy	_
15-41	2589-2590	,	_
15-42	2591-2597	severe	_
15-43	2598-2605	medical	_
15-44	2606-2614	disorder	_
15-45	2615-2617	or	_
15-46	2618-2632	antidepressant	_
15-47	2633-2634	.	_

16-1	2635-2637	In	_
16-2	2638-2641	the	_
16-3	2642-2647	month	_
16-4	2648-2654	before	_
16-5	2655-2665	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-6	2666-2674	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-7	2675-2684	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-8	2685-2692	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-9	2693-2694	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-10	2695-2699	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-11	2700-2701	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-12	2702-2703	,	_
16-13	2704-2707	the	_
16-14	2708-2716	positive	_
16-15	2717-2720	and	_
16-16	2721-2729	negative	_
16-17	2730-2738	symptoms	_
16-18	2739-2741	of	_
16-19	2742-2746	each	_
16-20	2747-2754	patient	_
16-21	2755-2759	were	_
16-22	2760-2773	independently	_
16-23	2774-2782	assessed	_
16-24	2783-2788	using	_
16-25	2789-2792	the	_
16-26	2793-2798	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-27	2799-2802	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-28	2803-2813	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-29	2814-2816	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-30	2817-2825	Positive	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-31	2826-2834	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-32	2835-2836	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-33	2837-2841	SAPS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-34	2842-2843	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofPositiveSymptoms
16-35	2844-2847	and	_
16-36	2848-2851	the	_
16-37	2852-2857	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-38	2858-2861	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-39	2862-2865	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-40	2866-2876	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-41	2877-2879	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-42	2880-2888	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-43	2889-2897	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-44	2898-2899	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-45	2900-2904	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-46	2905-2906	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-47	2907-2908	.	_

17-1	2909-2921	Additionally	_
17-2	2922-2923	,	_
17-3	2924-2926	we	_
17-4	2927-2931	also	_
17-5	2932-2941	evaluated	_
17-6	2942-2945	the	_
17-7	2946-2955	cognitive	_
17-8	2956-2964	function	_
17-9	2965-2967	of	_
17-10	2968-2971	all	_
17-11	2972-2984	participants	_
17-12	2985-2987	by	_
17-13	2988-2993	using	_
17-14	2994-2995	a	_
17-15	2996-3006	parametric	_
17-16	3007-3013	n-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-17	3014-3018	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-18	3019-3025	during	_
17-19	3026-3029	the	_
17-20	3030-3034	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
17-21	3035-3039	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
17-22	3040-3041	.	_

18-1	3042-3052	Twenty-one	_
18-2	3053-3065	right-handed	_
18-3	3066-3069	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-4	3070-3077	matched	_
18-5	3078-3081	for	_
18-6	3082-3085	age	_
18-7	3086-3087	,	_
18-8	3088-3091	sex	_
18-9	3092-3093	,	_
18-10	3094-3097	and	_
18-11	3098-3103	years	_
18-12	3104-3106	of	_
18-13	3107-3116	education	_
18-14	3117-3121	were	_
18-15	3122-3131	recruited	_
18-16	3132-3136	from	_
18-17	3137-3140	the	_
18-18	3141-3145	city	_
18-19	3146-3148	of	_
18-20	3149-3157	Changsha	_
18-21	3158-3161	and	_
18-22	3162-3166	were	_
18-23	3167-3174	without	_
18-24	3175-3179	past	_
18-25	3180-3182	or	_
18-26	3183-3190	present	_
18-27	3191-3202	psychiatric	_
18-28	3203-3204	,	_
18-29	3205-3217	neurological	_
18-30	3218-3219	,	_
18-31	3220-3222	or	_
18-32	3223-3228	other	_
18-33	3229-3241	neurological	_
18-34	3242-3251	disorders	_
18-35	3252-3253	,	_
18-36	3254-3256	as	_
18-37	3257-3267	determined	_
18-38	3268-3270	by	_
18-39	3271-3273	an	_
18-40	3274-3285	abbreviated	_
18-41	3286-3293	version	_
18-42	3294-3296	of	_
18-43	3297-3300	the	_
18-44	3301-3314	Comprehensive	_
18-45	3315-3325	Assessment	_
18-46	3326-3328	of	_
18-47	3329-3337	Symptoms	_
18-48	3338-3341	and	_
18-49	3342-3349	History	_
18-50	3350-3351	.	_

19-1	3352-3360	Informed	_
19-2	3361-3368	consent	_
19-3	3369-3372	was	_
19-4	3373-3378	fully	_
19-5	3379-3388	explained	_
19-6	3389-3391	to	_
19-7	3392-3396	each	_
19-8	3397-3408	participant	_
19-9	3409-3410	,	_
19-10	3411-3414	who	_
19-11	3415-3419	then	_
19-12	3420-3424	each	_
19-13	3425-3429	gave	_
19-14	3430-3437	written	_
19-15	3438-3446	informed	_
19-16	3447-3454	consent	_
19-17	3455-3456	.	_

20-1	3457-3469	Demographics	_
20-2	3470-3473	and	_
20-3	3474-3482	clinical	_
20-4	3483-3498	characteristics	_
20-5	3499-3501	of	_
20-6	3502-3505	all	_
20-7	3506-3518	participants	_
20-8	3519-3522	are	_
20-9	3523-3528	shown	_
20-10	3529-3531	in	_
20-11	3532-3537	Table	_
20-12	3538-3539	1	_
20-13	3540-3541	.	_

21-1	3542-3546	Part	_
21-2	3547-3549	of	_
21-3	3550-3558	patients	_
21-4	3559-3562	and	_
21-5	3563-3570	healthy	_
21-6	3571-3579	controls	_
21-7	3580-3584	have	_
21-8	3585-3589	been	_
21-9	3590-3596	choose	_
21-10	3597-3599	to	_
21-11	3600-3611	investigate	_
21-12	3612-3621	disrupted	_
21-13	3622-3631	effective	_
21-14	3632-3644	connectivity	_
21-15	3645-3647	in	_
21-16	3648-3661	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
21-17	3662-3670	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
21-18	3671-3672	,	_
21-19	3673-3678	while	_
21-20	3679-3683	Zhou	_
21-21	3684-3686	et	_
21-22	3687-3689	al	_
21-23	3690-3691	.	_

22-1	3692-3696	have	_
22-2	3697-3703	choose	_
22-3	3704-3709	other	_
22-4	3710-3714	part	_
22-5	3715-3717	of	_
22-6	3718-3726	patients	_
22-7	3727-3729	to	_
22-8	3730-3737	provide	_
22-9	3738-3746	evidence	_
22-10	3747-3750	for	_
22-11	3751-3762	inefficient	_
22-12	3763-3770	default	_
22-13	3771-3775	mode	_
22-14	3776-3783	network	_
22-15	3784-3785	(	_
22-16	3786-3789	DMN	_
22-17	3790-3791	)	_
22-18	3792-3803	suppression	_
22-19	3804-3806	in	_
22-20	3807-3820	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-21	3821-3825	with	_
22-22	3826-3835	cognitive	_
22-23	3836-3844	deficits	_
22-24	3845-3846	.	_

23-1	3847-3851	This	_
23-2	3852-3857	study	_
23-3	3858-3861	was	_
23-4	3862-3870	approved	_
23-5	3871-3873	by	_
23-6	3874-3877	the	_
23-7	3878-3884	Ethics	_
23-8	3885-3894	Committee	_
23-9	3895-3897	of	_
23-10	3898-3901	the	_
23-11	3902-3908	Second	_
23-12	3909-3916	Xiangya	_
23-13	3917-3925	Hospital	_
23-14	3926-3927	,	_
23-15	3928-3935	Central	_
23-16	3936-3941	South	_
23-17	3942-3952	University	_
23-18	3953-3954	,	_
23-19	3955-3960	Hunan	_
23-20	3961-3962	,	_
23-21	3963-3968	China	_
23-22	3969-3970	.	_

24-1	3971-3977	N-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-2	3978-3982	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-3	3983-3984	A	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-4	3985-3991	letter	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-5	3992-3998	n-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-6	3999-4003	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-7	4004-4007	was	_
24-8	4008-4017	performed	_
24-9	4018-4020	on	_
24-10	4021-4035	NordicNeurolab	http://maven.renci.org/NeuroBridge/neurobridge#DiabeticNeuropathy
24-11	4036-4037	’	_
24-12	4038-4039	s	_
24-13	4040-4044	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
24-14	4045-4053	hardware	_
24-15	4054-4060	system	_
24-16	4061-4063	as	_
24-17	4064-4074	previously	_
24-18	4075-4084	described	_
24-19	4085-4086	.	_

25-1	4087-4094	Briefly	_
25-2	4095-4096	,	_
25-3	4097-4100	the	_
25-4	4101-4105	task	_
25-5	4106-4114	included	_
25-6	4115-4118	two	_
25-7	4119-4130	alternating	_
25-8	4131-4141	conditions	_
25-9	4142-4143	:	_
25-10	4144-4147	the	_
25-11	4148-4149	‘	_
25-12	4150-4156	0-back	_
25-13	4157-4158	’	_
25-14	4159-4168	condition	_
25-15	4169-4172	and	_
25-16	4173-4176	the	_
25-17	4177-4178	‘	_
25-18	4179-4185	2-back	_
25-19	4186-4187	’	_
25-20	4188-4197	condition	_
25-21	4198-4199	.	_

26-1	4200-4202	In	_
26-2	4203-4206	the	_
26-3	4207-4213	0-back	_
26-4	4214-4223	condition	_
26-5	4224-4225	,	_
26-6	4226-4234	subjects	_
26-7	4235-4242	pressed	_
26-8	4243-4246	the	_
26-9	4247-4252	right	_
26-10	4253-4259	button	_
26-11	4260-4262	if	_
26-12	4263-4266	the	_
26-13	4267-4273	letter	_
26-14	4274-4275	x	_
26-15	4276-4284	appeared	_
26-16	4285-4286	;	_
26-17	4287-4296	otherwise	_
26-18	4297-4298	,	_
26-19	4299-4302	the	_
26-20	4303-4307	left	_
26-21	4308-4314	button	_
26-22	4315-4318	was	_
26-23	4319-4326	pressed	_
26-24	4327-4328	.	_

27-1	4329-4331	In	_
27-2	4332-4335	the	_
27-3	4336-4342	2-back	_
27-4	4343-4352	condition	_
27-5	4353-4354	,	_
27-6	4355-4363	subjects	_
27-7	4364-4371	pressed	_
27-8	4372-4375	the	_
27-9	4376-4381	right	_
27-10	4382-4388	button	_
27-11	4389-4393	when	_
27-12	4394-4397	the	_
27-13	4398-4404	letter	_
27-14	4405-4408	was	_
27-15	4409-4418	identical	_
27-16	4419-4421	to	_
27-17	4422-4425	the	_
27-18	4426-4429	one	_
27-19	4430-4439	presented	_
27-20	4440-4443	two	_
27-21	4444-4450	trials	_
27-22	4451-4461	previously	_
27-23	4462-4463	;	_
27-24	4464-4473	otherwise	_
27-25	4474-4475	,	_
27-26	4476-4479	the	_
27-27	4480-4484	left	_
27-28	4485-4491	button	_
27-29	4492-4495	was	_
27-30	4496-4503	pressed	_
27-31	4504-4505	.	_

28-1	4506-4509	The	_
28-2	4510-4514	scan	_
28-3	4515-4522	session	_
28-4	4523-4532	comprised	_
28-5	4533-4537	four	_
28-6	4538-4544	2-back	_
28-7	4545-4548	and	_
28-8	4549-4553	four	_
28-9	4554-4560	0-back	_
28-10	4561-4567	blocks	_
28-11	4568-4571	for	_
28-12	4572-4573	8	_
28-13	4574-4577	min	_
28-14	4578-4581	and	_
28-15	4582-4584	20	_
28-16	4585-4587	s.	_
28-17	4588-4592	Each	_
28-18	4593-4598	block	_
28-19	4599-4602	was	_
28-20	4603-4611	preceded	_
28-21	4612-4614	by	_
28-22	4615-4616	a	_
28-23	4617-4621	text	_
28-24	4622-4633	instruction	_
28-25	4634-4639	shown	_
28-26	4640-4643	for	_
28-27	4644-4645	2	_
28-28	4646-4647	s	_
28-29	4648-4649	;	_
28-30	4650-4662	participants	_
28-31	4663-4667	were	_
28-32	4668-4672	then	_
28-33	4673-4678	shown	_
28-34	4679-4681	20	_
28-35	4682-4688	trials	_
28-36	4689-4690	,	_
28-37	4691-4693	of	_
28-38	4694-4699	which	_
28-39	4700-4701	7	_
28-40	4702-4708	trials	_
28-41	4709-4713	were	_
28-42	4714-4717	the	_
28-43	4718-4724	target	_
28-44	4725-4731	trials	_
28-45	4732-4733	.	_

29-1	4734-4738	Each	_
29-2	4739-4744	trial	_
29-3	4745-4748	was	_
29-4	4749-4758	presented	_
29-5	4759-4762	for	_
29-6	4763-4766	500	_
29-7	4767-4769	ms	_
29-8	4770-4771	,	_
29-9	4772-4780	followed	_
29-10	4781-4783	by	_
29-11	4784-4786	an	_
29-12	4787-4799	inter-letter	_
29-13	4800-4808	interval	_
29-14	4809-4811	of	_
29-15	4812-4816	1500	_
29-16	4817-4820	ms.	_
29-17	4821-4827	Before	_
29-18	4828-4831	the	_
29-19	4832-4836	real	_
29-20	4837-4841	task	_
29-21	4842-4843	,	_
29-22	4844-4847	all	_
29-23	4848-4860	participants	_
29-24	4861-4867	needed	_
29-25	4868-4876	practice	_
29-26	4877-4879	to	_
29-27	4880-4885	reach	_
29-28	4886-4889	the	_
29-29	4890-4898	required	_
29-30	4899-4907	accuracy	_
29-31	4908-4910	of	_
29-32	4911-4918	correct	_
29-33	4919-4928	responses	_
29-34	4929-4931	80	_
29-35	4932-4933	%	_
29-36	4934-4935	.	_

30-1	4936-4947	Statistical	_
30-2	4948-4956	analysis	_
30-3	4957-4962	Three	_
30-4	4963-4971	patients	_
30-5	4972-4976	with	_
30-6	4977-4988	significant	_
30-7	4989-4993	head	_
30-8	4994-5000	motion	_
30-9	5001-5002	(	_
30-10	5003-5010	maximum	_
30-11	5011-5017	motion	_
30-12	5018-5024	larger	_
30-13	5025-5029	than	_
30-14	5030-5032	2°	_
30-15	5033-5035	or	_
30-16	5036-5037	2	_
30-17	5038-5040	mm	_
30-18	5041-5042	)	_
30-19	5043-5045	or	_
30-20	5046-5051	other	_
30-21	5052-5061	artifacts	_
30-22	5062-5066	were	_
30-23	5067-5076	discarded	_
30-24	5077-5078	.	_

31-1	5079-5082	The	_
31-2	5083-5092	remaining	_
31-3	5093-5101	patients	_
31-4	5102-5106	were	_
31-5	5107-5113	placed	_
31-6	5114-5118	into	_
31-7	5119-5125	either	_
31-8	5126-5129	the	_
31-9	5130-5135	SZ-CD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
31-10	5136-5141	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
31-11	5142-5144	or	_
31-12	5145-5148	the	_
31-13	5149-5155	SZ-NCD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
31-14	5156-5161	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
31-15	5162-5164	on	_
31-16	5165-5168	the	_
31-17	5169-5174	basis	_
31-18	5175-5177	of	_
31-19	5178-5183	their	_
31-20	5184-5192	accuracy	_
31-21	5193-5195	in	_
31-22	5196-5199	the	_
31-23	5200-5206	2-back	_
31-24	5207-5211	task	_
31-25	5212-5213	.	_

32-1	5214-5217	The	_
32-2	5218-5221	raw	_
32-3	5222-5231	cognitive	_
32-4	5232-5238	scores	_
32-5	5239-5243	were	_
32-6	5244-5254	calculated	_
32-7	5255-5257	as	_
32-8	5258-5261	the	_
32-9	5262-5269	average	_
32-10	5270-5272	of	_
32-11	5273-5276	the	_
32-12	5277-5283	Target	_
32-13	5284-5287	and	_
32-14	5288-5298	Non-target	_
32-15	5299-5309	accuracies	_
32-16	5310-5312	in	_
32-17	5313-5316	the	_
32-18	5317-5323	2-back	_
32-19	5324-5328	task	_
32-20	5329-5330	.	_

33-1	5331-5335	Then	_
33-2	5336-5337	,	_
33-3	5338-5342	each	_
33-4	5343-5346	raw	_
33-5	5347-5356	cognitive	_
33-6	5357-5362	score	_
33-7	5363-5366	was	_
33-8	5367-5375	normally	_
33-9	5376-5387	distributed	_
33-10	5388-5392	with	_
33-11	5393-5394	a	_
33-12	5395-5399	mean	_
33-13	5400-5402	of	_
33-14	5403-5404	0	_
33-15	5405-5408	and	_
33-16	5409-5410	a	_
33-17	5411-5419	standard	_
33-18	5420-5429	deviation	_
33-19	5430-5432	of	_
33-20	5433-5434	1	_
33-21	5435-5436	.	_

34-1	5437-5445	Patients	_
34-2	5446-5450	were	_
34-3	5451-5457	placed	_
34-4	5458-5460	in	_
34-5	5461-5464	the	_
34-6	5465-5470	SZ-CD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
34-7	5471-5476	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
34-8	5477-5479	if	_
34-9	5480-5485	their	_
34-10	5486-5496	normalized	_
34-11	5497-5506	cognitive	_
34-12	5507-5512	score	_
34-13	5513-5516	was	_
34-14	5517-5521	more	_
34-15	5522-5526	than	_
34-16	5527-5528	1	_
34-17	5529-5531	SD	_
34-18	5532-5537	below	_
34-19	5538-5541	the	_
34-20	5542-5551	normative	_
34-21	5552-5556	mean	_
34-22	5557-5558	.	_

35-1	5559-5562	The	_
35-2	5563-5571	approach	_
35-3	5572-5580	resulted	_
35-4	5581-5583	in	_
35-5	5584-5592	eighteen	_
35-6	5593-5601	patients	_
35-7	5602-5610	assigned	_
35-8	5611-5613	to	_
35-9	5614-5617	the	_
35-10	5618-5623	SZ-CD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
35-11	5624-5629	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
35-12	5630-5633	and	_
35-13	5634-5641	sixteen	_
35-14	5642-5650	patients	_
35-15	5651-5653	to	_
35-16	5654-5657	the	_
35-17	5658-5664	SZ-NCD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
35-18	5665-5670	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
35-19	5671-5672	.	_

36-1	5673-5684	Furthermore	_
36-2	5685-5686	,	_
36-3	5687-5690	the	_
36-4	5691-5698	Digital	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-5	5699-5705	Symbol	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-6	5706-5718	Substitution	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-7	5719-5723	Test	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-8	5724-5725	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-9	5726-5730	DSST	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-10	5731-5732	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-11	5733-5736	and	_
36-12	5737-5740	the	_
36-13	5741-5752	Information	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
36-14	5753-5761	Subscale	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
36-15	5762-5764	of	http://maven.renci.org/NeuroBridge/neurobridge#ReportedMeasurement
36-16	5765-5773	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-17	5774-5779	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-18	5780-5792	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-19	5793-5798	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-20	5799-5806	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-21	5807-5814	Revised	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-22	5815-5816	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-23	5817-5824	WAIS-CR	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-24	5825-5826	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
36-25	5827-5828	(	_
36-26	5829-5834	Table	_
36-27	5835-5836	1	_
36-28	5837-5838	)	_
36-29	5839-5843	were	_
36-30	5844-5848	used	_
36-31	5849-5851	to	_
36-32	5852-5859	measure	_
36-33	5860-5863	two	_
36-34	5864-5869	other	_
36-35	5870-5879	important	_
36-36	5880-5889	cognitive	_
36-37	5890-5899	functions	_
36-38	5900-5901	,	_
36-39	5902-5913	information	_
36-40	5914-5924	processing	_
36-41	5925-5930	speed	_
36-42	5931-5934	and	_
36-43	5935-5941	verbal	_
36-44	5942-5955	comprehension	_
36-45	5956-5957	,	_
36-46	5958-5970	respectively	_
36-47	5971-5972	.	_

37-1	5973-5978	There	_
37-2	5979-5983	were	_
37-3	5984-5995	significant	_
37-4	5996-6007	differences	_
37-5	6008-6015	between	_
37-6	6016-6019	the	_
37-7	6020-6025	SZ-CD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
37-8	6026-6029	and	_
37-9	6030-6036	SZ-NCD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
37-10	6037-6043	groups	_
37-11	6044-6046	in	_
37-12	6047-6058	information	_
37-13	6059-6069	processing	_
37-14	6070-6075	speed	_
37-15	6076-6079	and	_
37-16	6080-6086	verbal	_
37-17	6087-6100	comprehension	_
37-18	6101-6103	as	_
37-19	6104-6112	assessed	_
37-20	6113-6115	by	_
37-21	6116-6117	a	_
37-22	6118-6128	two-sample	_
37-23	6129-6135	t-test	_
37-24	6136-6141	using	_
37-25	6142-6145	IBM	_
37-26	6146-6150	SPSS	_
37-27	6151-6161	statistics	_
37-28	6162-6163	(	_
37-29	6164-6171	version	_
37-30	6172-6176	20.0	_
37-31	6177-6178	)	_
37-32	6179-6180	,	_
37-33	6181-6190	providing	_
37-34	6191-6198	further	_
37-35	6199-6206	support	_
37-36	6207-6210	for	_
37-37	6211-6214	our	_
37-38	6215-6223	criteria	_
37-39	6224-6225	.	_

38-1	6226-6231	Image	_
38-2	6232-6243	acquisition	_
38-3	6244-6247	All	_
38-4	6248-6263	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
38-5	6264-6275	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-6	6276-6282	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-7	6283-6287	were	_
38-8	6288-6296	acquired	_
38-9	6297-6299	in	_
38-10	6300-6303	the	_
38-11	6304-6314	Department	_
38-12	6315-6317	of	_
38-13	6318-6328	Psychiatry	_
38-14	6329-6330	,	_
38-15	6331-6337	Second	_
38-16	6338-6345	Xiangya	_
38-17	6346-6354	Hospital	_
38-18	6355-6357	of	_
38-19	6358-6365	Central	_
38-20	6366-6371	South	_
38-21	6372-6382	University	_
38-22	6383-6384	,	_
38-23	6385-6393	Changsha	_
38-24	6394-6395	,	_
38-25	6396-6401	China	_
38-26	6402-6403	,	_
38-27	6404-6409	using	_
38-28	6410-6411	a	_
38-29	6412-6423	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-30	6424-6426	3D	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
38-31	6427-6432	turbo	_
38-32	6433-6438	field	_
38-33	6439-6443	echo	_
38-34	6444-6446	on	_
38-35	6447-6448	a	_
38-36	6449-6456	Philips	_
38-37	6457-6465	Gyroscan	_
38-38	6466-6473	Achieva	_
38-39	6474-6477	3.0	_
38-40	6478-6483	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-41	6484-6487	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-42	6488-6495	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
38-43	6496-6500	with	_
38-44	6501-6504	the	_
38-45	6505-6514	following	_
38-46	6515-6525	parameters	_
38-47	6526-6527	:	_
38-48	6528-6538	repetition	_
38-49	6539-6543	time	_
38-50	6544-6545	=	_
38-51	6546-6549	7.5	_
38-52	6550-6552	ms	_
38-53	6553-6554	,	_
38-54	6555-6559	echo	_
38-55	6560-6564	time	_
38-56	6565-6566	=	_
38-57	6567-6570	3.7	_
38-58	6571-6573	ms	_
38-59	6574-6575	,	_
38-60	6576-6580	flip	_
38-61	6581-6586	angle	_
38-62	6587-6588	=	_
38-63	6589-6591	8°	_
38-64	6592-6593	,	_
38-65	6594-6599	field	_
38-66	6600-6602	of	_
38-67	6603-6607	view	_
38-68	6608-6609	=	_
38-69	6610-6613	240	_
38-70	6614-6615	×	_
38-71	6616-6619	240	_
38-72	6620-6623	mm2	_
38-73	6624-6625	,	_
38-74	6626-6637	acquisition	_
38-75	6638-6644	matrix	_
38-76	6645-6649	=256	_
38-77	6650-6651	×	_
38-78	6652-6655	200	_
38-79	6656-6657	,	_
38-80	6658-6663	voxel	_
38-81	6664-6674	resolution	_
38-82	6675-6678	1.0	_
38-83	6679-6680	×	_
38-84	6681-6684	1.0	_
38-85	6685-6686	×	_
38-86	6687-6690	1.0	_
38-87	6691-6694	mm3	_
38-88	6695-6696	,	_
38-89	6697-6702	slice	_
38-90	6703-6712	thickness	_
38-91	6713-6714	=	_
38-92	6715-6716	1	_
38-93	6717-6719	mm	_
38-94	6720-6721	,	_
38-95	6722-6725	gap	_
38-96	6726-6727	=	_
38-97	6728-6729	0	_
38-98	6730-6731	,	_
38-99	6732-6735	and	_
38-100	6736-6742	number	_
38-101	6743-6745	of	_
38-102	6746-6752	slices	_
38-103	6753-6754	=	_
38-104	6755-6758	180	_
38-105	6759-6760	.	_

39-1	6761-6771	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-2	6772-6775	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-3	6776-6782	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-4	6783-6787	were	_
39-5	6788-6797	collected	_
39-6	6798-6800	in	_
39-7	6801-6804	the	_
39-8	6805-6810	axial	_
39-9	6811-6820	direction	_
39-10	6821-6822	,	_
39-11	6823-6828	using	_
39-12	6829-6830	a	_
39-13	6831-6844	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-14	6845-6849	echo	_
39-15	6850-6856	planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
39-16	6857-6864	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
39-17	6865-6866	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
39-18	6867-6870	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
39-19	6871-6872	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
39-20	6873-6881	sequence	_
39-21	6882-6883	:	_
39-22	6884-6894	repetition	_
39-23	6895-6899	time	_
39-24	6900-6901	(	_
39-25	6902-6904	TR	_
39-26	6905-6906	)	_
39-27	6907-6908	=	_
39-28	6909-6913	2000	_
39-29	6914-6916	ms	_
39-30	6917-6918	,	_
39-31	6919-6923	echo	_
39-32	6924-6928	time	_
39-33	6929-6930	(	_
39-34	6931-6933	TE	_
39-35	6934-6935	)	_
39-36	6936-6937	=	_
39-37	6938-6940	30	_
39-38	6941-6943	ms	_
39-39	6944-6945	,	_
39-40	6946-6952	matrix	_
39-41	6953-6954	=	_
39-42	6955-6957	64	_
39-43	6958-6959	×	_
39-44	6960-6962	64	_
39-45	6963-6964	,	_
39-46	6965-6971	slices	_
39-47	6972-6973	=	_
39-48	6974-6976	36	_
39-49	6977-6978	,	_
39-50	6979-6984	slice	_
39-51	6985-6994	thickness	_
39-52	6995-6996	=	_
39-53	6997-6998	4	_
39-54	6999-7001	mm	_
39-55	7002-7003	,	_
39-56	7004-7007	gap	_
39-57	7008-7010	=0	_
39-58	7011-7013	mm	_
39-59	7014-7015	,	_
39-60	7016-7020	flip	_
39-61	7021-7026	angle	_
39-62	7027-7028	=	_
39-63	7029-7032	90°	_
39-64	7033-7034	,	_
39-65	7035-7038	FOV	_
39-66	7039-7041	24	_
39-67	7042-7043	×	_
39-68	7044-7046	24	_
39-69	7047-7049	cm	_
39-70	7050-7051	,	_
39-71	7052-7055	250	_
39-72	7056-7060	time	_
39-73	7061-7067	points	_
39-74	7068-7069	.	_

40-1	7070-7073	The	_
40-2	7074-7078	scan	_
40-3	7079-7085	lasted	_
40-4	7086-7089	for	_
40-5	7090-7102	8min20s.Foam	_
40-6	7103-7107	pads	_
40-7	7108-7111	and	_
40-8	7112-7120	earplugs	_
40-9	7121-7125	were	_
40-10	7126-7130	used	_
40-11	7131-7133	to	_
40-12	7134-7142	minimize	_
40-13	7143-7147	head	_
40-14	7148-7154	motion	_
40-15	7155-7158	and	_
40-16	7159-7166	scanner	_
40-17	7167-7172	noise	_
40-18	7173-7174	.	_

41-1	7175-7178	All	_
41-2	7179-7184	scans	_
41-3	7185-7189	were	_
41-4	7190-7199	inspected	_
41-5	7200-7203	for	_
41-6	7204-7211	quality	_
41-7	7212-7219	control	_
41-8	7220-7221	.	_

42-1	7222-7227	Image	_
42-2	7228-7238	processing	_
42-3	7239-7249	Structural	_
42-4	7250-7256	images	_
42-5	7257-7265	analysis	_
42-6	7266-7269	was	_
42-7	7270-7279	performed	_
42-8	7280-7285	using	_
42-9	7286-7289	the	_
42-10	7290-7294	VBM8	_
42-11	7295-7302	toolbox	_
42-12	7303-7310	version	_
42-13	7311-7315	1.19	_
42-14	7316-7317	,	_
42-15	7318-7320	an	_
42-16	7321-7330	extension	_
42-17	7331-7333	of	_
42-18	7334-7337	the	_
42-19	7338-7349	Statistical	_
42-20	7350-7360	Parametric	_
42-21	7361-7368	Mapping	_
42-22	7369-7370	8	_
42-23	7371-7372	(	_
42-24	7373-7377	SPM8	_
42-25	7378-7379	)	_
42-26	7380-7388	software	_
42-27	7389-7396	package	_
42-28	7397-7398	.	_

43-1	7399-7402	The	_
43-2	7403-7407	main	_
43-3	7408-7417	procedure	_
43-4	7418-7426	included	_
43-5	7427-7430	the	_
43-6	7431-7440	following	_
43-7	7441-7446	steps	_
43-8	7447-7448	:	_
43-9	7449-7450	1	_
43-10	7451-7452	)	_
43-11	7453-7461	checking	_
43-12	7462-7465	for	_
43-13	7466-7473	scanner	_
43-14	7474-7483	artifacts	_
43-15	7484-7487	and	_
43-16	7488-7493	gross	_
43-17	7494-7504	anatomical	_
43-18	7505-7518	abnormalities	_
43-19	7519-7522	for	_
43-20	7523-7527	each	_
43-21	7528-7535	subject	_
43-22	7536-7537	;	_
43-23	7538-7539	2	_
43-24	7540-7541	)	_
43-25	7542-7549	setting	_
43-26	7550-7553	the	_
43-27	7554-7559	image	_
43-28	7560-7566	origin	_
43-29	7567-7569	to	_
43-30	7570-7573	the	_
43-31	7574-7582	anterior	_
43-32	7583-7593	commissure	_
43-33	7594-7595	;	_
43-34	7596-7597	3	_
43-35	7598-7599	)	_
43-36	7600-7610	segmenting	_
43-37	7611-7614	the	_
43-38	7615-7621	images	_
43-39	7622-7626	into	_
43-40	7627-7631	gray	_
43-41	7632-7638	matter	_
43-42	7639-7642	and	_
43-43	7643-7648	white	_
43-44	7649-7655	matter	_
43-45	7656-7662	images	_
43-46	7663-7664	;	_
43-47	7665-7666	4	_
43-48	7667-7668	)	_
43-49	7669-7674	using	_
43-50	7675-7678	the	_
43-51	7679-7685	DARTEL	_
43-52	7686-7693	toolbox	_
43-53	7694-7696	on	_
43-54	7697-7701	SPM8	_
43-55	7702-7704	to	_
43-56	7705-7712	produce	_
43-57	7713-7714	a	_
43-58	7715-7731	high-dimensional	_
43-59	7732-7745	normalization	_
43-60	7746-7754	protocol	_
43-61	7755-7756	;	_
43-62	7757-7760	and	_
43-63	7761-7762	5	_
43-64	7763-7764	)	_
43-65	7765-7774	smoothing	_
43-66	7775-7778	the	_
43-67	7779-7790	unmodulated	_
43-68	7791-7795	gray	_
43-69	7796-7802	matter	_
43-70	7803-7809	images	_
43-71	7810-7814	with	_
43-72	7815-7816	a	_
43-73	7817-7825	Gaussian	_
43-74	7826-7832	kernel	_
43-75	7833-7835	of	_
43-76	7836-7840	8-mm	_
43-77	7841-7851	full-width	_
43-78	7852-7854	at	_
43-79	7855-7867	half-maximum	_
43-80	7868-7869	(	_
43-81	7870-7874	FWHM	_
43-82	7875-7876	)	_
43-83	7877-7878	.	_

44-1	7879-7889	Voxel-wise	_
44-2	7890-7901	differences	_
44-3	7902-7904	in	_
44-4	7905-7908	the	_
44-5	7909-7912	GMD	_
44-6	7913-7915	in	_
44-7	7916-7919	the	_
44-8	7920-7933	intracerebral	_
44-9	7934-7940	cortex	_
44-10	7941-7945	were	_
44-11	7946-7954	assessed	_
44-12	7955-7960	using	_
44-13	7961-7971	voxel-wise	_
44-14	7972-7975	one	_
44-15	7976-7979	way	_
44-16	7980-7988	analysis	_
44-17	7989-7991	of	_
44-18	7992-8000	variance	_
44-19	8001-8002	(	_
44-20	8003-8008	ANOVA	_
44-21	8009-8010	)	_
44-22	8011-8017	across	_
44-23	8018-8021	the	_
44-24	8022-8027	three	_
44-25	8028-8035	subject	_
44-26	8036-8042	groups	_
44-27	8043-8048	after	_
44-28	8049-8060	controlling	_
44-29	8061-8064	for	_
44-30	8065-8068	age	_
44-31	8069-8072	and	_
44-32	8073-8079	gender	_
44-33	8080-8081	(	_
44-34	8082-8087	voxel	_
44-35	8088-8092	wise	_
44-36	8093-8094	p	_
44-37	8095-8096	<	_
44-38	8097-8101	0.05	_
44-39	8102-8105	and	_
44-40	8106-8113	cluster	_
44-41	8114-8118	size	_
44-42	8119-8120	>	_
44-43	8121-8131	3554voxels	_
44-44	8132-8133	)	_
44-45	8134-8135	.	_

45-1	8136-8144	Multiple	_
45-2	8145-8156	comparisons	_
45-3	8157-8161	were	_
45-4	8162-8171	corrected	_
45-5	8172-8177	using	_
45-6	8178-8183	Monte	_
45-7	8184-8189	Carlo	_
45-8	8190-8201	simulations	_
45-9	8202-8204	in	_
45-10	8205-8208	the	_
45-11	8209-8222	Resting-State	_
45-12	8223-8227	fMRI	_
45-13	8228-8232	Data	_
45-14	8233-8241	Analysis	_
45-15	8242-8249	Toolkit	_
45-16	8250-8251	(	_
45-17	8252-8256	REST	_
45-18	8257-8258	,	_
45-19	8259-8263	http	_
45-20	8264-8265	:	_
45-21	8266-8285	//rest.restfmri.net	_
45-22	8286-8287	)	_
45-23	8288-8289	.	_

46-1	8290-8297	Minimum	_
46-2	8298-8305	cluster	_
46-3	8306-8310	size	_
46-4	8311-8314	was	_
46-5	8315-8325	determined	_
46-6	8326-8328	by	_
46-7	8329-8337	AlphaSim	_
46-8	8338-8339	.	_

47-1	8340-8350	Restricted	_
47-2	8351-8353	to	_
47-3	8354-8357	the	_
47-4	8358-8363	above	_
47-5	8364-8370	voxels	_
47-6	8371-8381	identified	_
47-7	8382-8384	by	_
47-8	8385-8390	ANOVA	_
47-9	8391-8392	,	_
47-10	8393-8406	between-group	_
47-11	8407-8418	differences	_
47-12	8419-8421	in	_
47-13	8422-8426	gray	_
47-14	8427-8433	matter	_
47-15	8434-8443	densities	_
47-16	8444-8448	were	_
47-17	8449-8455	tested	_
47-18	8456-8461	using	_
47-19	8462-8470	post-hoc	_
47-20	8471-8476	tests	_
47-21	8477-8478	.	_

48-1	8479-8482	The	_
48-2	8483-8487	same	_
48-3	8488-8497	threshold	_
48-4	8498-8508	adjustment	_
48-5	8509-8515	method	_
48-6	8516-8519	was	_
48-7	8520-8524	used	_
48-8	8525-8526	,	_
48-9	8527-8532	SZ-CD	_
48-10	8533-8536	and	_
48-11	8537-8540	HCs	_
48-12	8541-8542	(	_
48-13	8543-8548	voxel	_
48-14	8549-8553	size	_
48-15	8554-8555	p	_
48-16	8556-8557	<	_
48-17	8558-8562	0.05	_
48-18	8563-8564	,	_
48-19	8565-8572	cluster	_
48-20	8573-8577	size	_
48-21	8578-8579	>	_
48-22	8580-8590	3152voxels	_
48-23	8591-8592	)	_
48-24	8593-8594	,	_
48-25	8595-8601	SZ-NCD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
48-26	8602-8605	and	_
48-27	8606-8609	HCs	_
48-28	8610-8611	(	_
48-29	8612-8617	voxel	_
48-30	8618-8622	size	_
48-31	8623-8624	p	_
48-32	8625-8626	<	_
48-33	8627-8631	0.05	_
48-34	8632-8633	,	_
48-35	8634-8641	cluster	_
48-36	8642-8646	size	_
48-37	8647-8648	>	_
48-38	8649-8659	3369voxels	_
48-39	8660-8661	)	_
48-40	8662-8663	,	_
48-41	8664-8669	SZ-CD	_
48-42	8670-8673	and	_
48-43	8674-8680	SZ-NCD	_
48-44	8681-8682	(	_
48-45	8683-8688	voxel	_
48-46	8689-8693	size	_
48-47	8694-8695	p	_
48-48	8696-8697	<	_
48-49	8698-8702	0.05	_
48-50	8703-8704	,	_
48-51	8705-8712	cluster	_
48-52	8713-8717	size	_
48-53	8718-8719	>	_
48-54	8720-8724	3380	_
48-55	8725-8731	voxels	_
48-56	8732-8733	)	_
48-57	8734-8735	,	_
48-58	8736-8741	which	_
48-59	8742-8746	were	_
48-60	8747-8757	equivalent	_
48-61	8758-8760	to	_
48-62	8761-8763	an	_
48-63	8764-8772	AlphaSim	_
48-64	8773-8783	correction	_
48-65	8784-8793	threshold	_
48-66	8794-8796	of	_
48-67	8797-8798	p	_
48-68	8799-8800	<	_
48-69	8801-8805	0.05	_
48-70	8806-8807	.	_

49-1	8808-8811	For	_
49-2	8812-8818	visual	_
49-3	8819-8830	observation	_
49-4	8831-8832	,	_
49-5	8833-8836	the	_
49-6	8837-8848	significant	_
49-7	8849-8855	voxels	_
49-8	8856-8860	were	_
49-9	8861-8869	overlaid	_
49-10	8870-8874	onto	_
49-11	8875-8876	a	_
49-12	8877-8892	high-definition	_
49-13	8893-8904	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
49-14	8905-8910	brain	_
49-15	8911-8919	template	_
49-16	8920-8922	to	_
49-17	8923-8927	show	_
49-18	8928-8933	group	_
49-19	8934-8945	differences	_
49-20	8946-8947	.	_

50-1	8948-8951	The	_
50-2	8952-8959	average	_
50-3	8960-8973	morphological	_
50-4	8974-8983	anomalies	_
50-5	8984-8986	in	_
50-6	8987-8991	each	_
50-7	8992-9003	significant	_
50-8	9004-9011	cluster	_
50-9	9012-9016	from	_
50-10	9017-9021	both	_
50-11	9022-9024	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
50-12	9025-9032	patient	_
50-13	9033-9039	groups	_
50-14	9040-9043	and	_
50-15	9044-9047	HCs	_
50-16	9048-9052	were	_
50-17	9053-9062	extracted	_
50-18	9063-9064	.	_

51-1	9065-9068	GMD	_
51-2	9069-9080	comparisons	_
51-3	9081-9086	among	_
51-4	9087-9090	the	_
51-5	9091-9096	three	_
51-6	9097-9103	groups	_
51-7	9104-9107	and	_
51-8	9108-9115	between	_
51-9	9116-9120	each	_
51-10	9121-9125	pair	_
51-11	9126-9128	of	_
51-12	9129-9135	groups	_
51-13	9136-9140	were	_
51-14	9141-9145	also	_
51-15	9146-9154	assessed	_
51-16	9155-9157	by	_
51-17	9158-9163	ANOVA	_
51-18	9164-9169	using	_
51-19	9170-9173	IBM	_
51-20	9174-9178	SPSS	_
51-21	9179-9189	statistics	_
51-22	9190-9191	(	_
51-23	9192-9199	version	_
51-24	9200-9204	20.0	_
51-25	9205-9206	)	_
51-26	9207-9208	.	_

52-1	9209-9216	Receive	_
52-2	9217-9226	operation	_
52-3	9227-9232	curve	_
52-4	9233-9234	(	_
52-5	9235-9238	ROC	_
52-6	9239-9240	)	_
52-7	9241-9246	could	_
52-8	9247-9257	illustrate	_
52-9	9258-9261	the	_
52-10	9262-9272	diagnostic	_
52-11	9273-9280	ability	_
52-12	9281-9283	of	_
52-13	9284-9285	a	_
52-14	9286-9292	binary	_
52-15	9293-9303	classifier	_
52-16	9304-9310	system	_
52-17	9311-9315	when	_
52-18	9316-9325	different	_
52-19	9326-9340	discrimination	_
52-20	9341-9350	threshold	_
52-21	9351-9354	was	_
52-22	9355-9358	set	_
52-23	9359-9360	,	_
52-24	9361-9366	which	_
52-25	9367-9370	was	_
52-26	9371-9378	usually	_
52-27	9379-9383	used	_
52-28	9384-9386	to	_
52-29	9387-9400	differentiate	_
52-30	9401-9404	the	_
52-31	9405-9413	patients	_
52-32	9414-9418	from	_
52-33	9419-9422	the	_
52-34	9423-9430	healthy	_
52-35	9431-9439	controls	_
52-36	9440-9442	or	_
52-37	9443-9450	between	_
52-38	9451-9460	subgroups	_
52-39	9461-9462	.	_

53-1	9463-9474	Furthermore	_
53-2	9475-9476	,	_
53-3	9477-9479	we	_
53-4	9480-9487	plotted	_
53-5	9488-9491	ROC	_
53-6	9492-9494	to	_
53-7	9495-9502	explore	_
53-8	9503-9510	whether	_
53-9	9511-9514	the	_
53-10	9515-9518	GMD	_
53-11	9519-9525	values	_
53-12	9526-9528	in	_
53-13	9529-9533	each	_
53-14	9534-9545	significant	_
53-15	9546-9553	cluster	_
53-16	9554-9559	could	_
53-17	9560-9573	differentiate	_
53-18	9574-9577	the	_
53-19	9578-9586	patients	_
53-20	9587-9591	from	_
53-21	9592-9595	the	_
53-22	9596-9603	healthy	_
53-23	9604-9612	controls	_
53-24	9613-9615	or	_
53-25	9616-9623	between	_
53-26	9624-9633	subgroups	_
53-27	9634-9635	.	_

54-1	9636-9646	Voxel–wise	_
54-2	9647-9654	Pearson	_
54-3	9655-9666	correlation	_
54-4	9667-9679	coefficients	_
54-5	9680-9684	were	_
54-6	9685-9695	calculated	_
54-7	9696-9703	between	_
54-8	9704-9707	the	_
54-9	9708-9711	GMD	_
54-10	9712-9718	values	_
54-11	9719-9721	of	_
54-12	9722-9733	significant	_
54-13	9734-9742	clusters	_
54-14	9743-9746	and	_
54-15	9747-9753	N-back	_
54-16	9754-9765	performance	_
54-17	9766-9772	scores	_
54-18	9773-9774	,	_
54-19	9775-9783	duration	_
54-20	9784-9786	of	_
54-21	9787-9794	illness	_
54-22	9795-9798	and	_
54-23	9799-9809	medication	_
54-24	9810-9815	doses	_
54-25	9816-9818	to	_
54-26	9819-9826	examine	_
54-27	9827-9836	potential	_
54-28	9837-9849	associations	_
54-29	9850-9857	between	_
54-30	9858-9871	morphological	_
54-31	9872-9880	deficits	_
54-32	9881-9884	and	_
54-33	9885-9893	clinical	_
54-34	9894-9902	symptoms	_
54-35	9903-9905	in	_
54-36	9906-9909	the	_
54-37	9910-9918	combined	_
54-38	9919-9924	SZ-CD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
54-39	9925-9928	and	_
54-40	9929-9935	SZ-NCD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
54-41	9936-9942	groups	_
54-42	9943-9948	after	_
54-43	9949-9960	controlling	_
54-44	9961-9964	age	_
54-45	9965-9968	and	_
54-46	9969-9972	sex	_
54-47	9973-9974	.	_

55-1	9975-9986	Correlation	_
55-2	9987-9995	analyses	_
55-3	9996-10000	were	_
55-4	10001-10010	performed	_
55-5	10011-10013	in	_
55-6	10014-10017	the	_
55-7	10018-10031	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-8	10032-10036	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
55-9	10037-10041	Data	_
55-10	10042-10050	Analysis	_
55-11	10051-10058	Toolkit	_
55-12	10059-10063	with	_
55-13	10064-10065	a	_
55-14	10066-10075	corrected	_
55-15	10076-10077	p	_
55-16	10078-10079	<	_
55-17	10080-10084	0.05	_
55-18	10085-10086	(	_
55-19	10087-10088	p	_
55-20	10089-10090	<	_
55-21	10091-10095	0.05	_
55-22	10096-10097	,	_
55-23	10098-10105	cluster	_
55-24	10106-10110	size	_
55-25	10111-10112	>	_
55-26	10113-10120	4484mm3	_
55-27	10121-10122	)	_
55-28	10123-10124	.	_

